glp-1 and addiction medications get at the heart of addiction: study – WashU Medicine Schematic illustration of the different

Lunetta, C

In our future work, we will be generating evidence on what alternative obesity treatment works best for whom, to help patients and providers make evidence-based decisions when continuing with a specific novel obesity medication is not possible, says Gasoyan

Morita K, Wang F, Patel K, Bueso-Ramos C, IssaGC, Song X, Zhang J, Tippen S, Thornton R, Coyle M, Little L, Gumbs C, Ravandi F, Kadia T, Daver N, Konopleva M, Andreeff M , Cortes JE, Garcia-Manero G, Jabbour EJ, Futreal A, Kantarjian HM, Takahashi

& Mruk, D

They are used in T2DM, obesity, and increasingly in cardiovascular risk reduction

Class Side Effects: Decreased Pressure in the Lower Oesophageal and the Pyloric Sphinctersafter the Administration of Dopamine Antagonists, Neuroleptics, Anti-emetics, L-NAME, Pentadecapeptide BPC 157 and L-Arginine